CIAM
HCWB icon

Caitong International Asset Management’s HCW Biologics HCWB Stock Holding History

Caitong International Asset Management’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10 Buy
+11
New +$62 ﹤0.01% 2639

Other funds holding HCWB

VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Caitong International Asset Management's HCWB Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in HCW Biologics (HCWB) in Q2 2026: 11 shares worth $10. The stake represents ﹤0.01% of the portfolio and ranks #2639 among its holdings.

7 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

  • Caitong International Asset Management held 11 shares of HCW Biologics worth $10 as of Q2 2026.
  • HCW Biologics was a new Caitong International Asset Management position in Q2 2026.
  • HCW Biologics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2639 holding.
  • 7 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.